John Dishuck, MD
Allergy & Immunology · Tuscaloosa, ALNPI 1225019706
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 415 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,499, more than ten times the $27 reported in 2020.
Across 415 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Sanofi$947
- Takeda Pharmaceuticals U.S.A., Inc.$793
- Regeneron Healthcare Solutions, Inc.$636
- Novartis$617
- plus $2K from 19 others
What the payments were for
- Food & beverage$8,45099%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 87 | $1,806 |
| GSK | 104 | $1,748 |
| Sanofi | 33 | $947 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $793 |
| Regeneron Healthcare Solutions, Inc. | 21 | $636 |
| Novartis | 29 | $617 |
| Amgen | 18 | $346 |
| Pfizer | 13 | $276 |
| Boehringer Ingelheim | 15 | $246 |
| Optinose US, Inc. | 12 | $232 |
| Genentech USA, Inc. | 6 | $139 |
| Grifols USA, LLC | 7 | $134 |
| Kaleo, Inc. | 7 | $126 |
| Hikma Pharmaceuticals USA | 4 | $73 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $64 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Galderma Laboratories, L.p. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Blueprint Medicines Corporation | 2 | $46 |
| Merck | 2 | $32 |
| Sanofi Pasteur Inc. | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Dermavant Sciences, Inc. | 1 | $18 |
| Jubilant Hollisterstier LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$8,511 in reported general payments places this provider in the 55th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 125 | $326,243 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $113,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $85,331 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $77,562 |
| NucalaMepolizumab | 19 | $67,017 |
| Dupixent SyringeDupilumab | 15 | $55,593 |
| Dupixent PenDupilumab | 12 | $46,055 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $30,676 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $30,134 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $16,516 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,476 |
| DuleraMometasone/Formoterol | 31 | $11,038 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $10,520 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $6,680 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $5,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,748 | $187,401216 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $793 | $113,87827 claims |
| Grifols USA, LLCGamunex-C | $134 | $77,56214 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,806 | $46,65092 claims |
| Boehringer IngelheimSpiriva Respimat | $246 | $13,47620 claims |
| MerckDulera | $32 | $11,03831 claims |
| Hikma Pharmaceuticals USAEpinephrine | $73 | $4,81117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Tuscaloosa
- John AndersonHomewood$789K
- Joseph ForesterCullman$719K
- William DavidsonDaphne$98K
- Thomas ScottBessemer$61K
- Thomas AtkinsonBirmingham$53K
- Njeri MainaBirmingham$44K
- Michael PolcariBirmingham$39K
- Karen BarkerDaphne$19K
- Lawrence SindelMobile$12K
- Robert GreerMobile$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.